NEW YORK (360Dx) — NuView Life Sciences has signed an agreement to evaluate its NV-VPAC1 urogenital cancer test on Aperture Bio’s screening platform, the company…
Read More
NEW YORK (360Dx) — NuView Life Sciences has signed an agreement to evaluate its NV-VPAC1 urogenital cancer test on Aperture Bio’s screening platform, the company…
© 2022 NuView Life Sciences. Terms of Use